The FDA has granted fast track designation for the development of evofosfamide for the treatment of metastatic or locally advanced unresectable pancreatic cancer in patients who were previously untreated, the manufacturer announced today.Evofosfamide (previously TH-302, Merck KGaA) is an investigational hypoxia-activated prodrug being developed in collaboration with Threshold Pharmaceuticals after a global license and co-development agreement in February 2012, according to the release. The compound is administered in combination with gemcitabine for the indication of pancreatic cancer and is thought to be activated under severe tumor hypoxic conditions.
No comments:
Post a Comment